Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences. […]
Advancements in breast cancer screening have increased cancer detection in patients previously not considered at risk for disease and have helped diagnose the disease at earlier stages. Breast cancer screening and early detection have been game changers for patients and their healthcare teams. Finding cancer early in patients opens up a variety of treatment options for both the initial and survivorship phases.
Researchers continue to push for progress in all aspects of screening, diagnosis and monitoring disease. Advances in our knowledge of breast cancer biology have led to the development of diagnostic methods that can help to tailor the treatment plan to specific types of breast cancer.
Lisa Whitmyer, a nine-year survivor of ER+, early-stage breast cancer and a team leader in the commercial division of Biotheranostics, Inc. spends most of her waking hours educating physicians about Breast Cancer Index, a test that provides information on risk of recurrence and likelihood of benefit from extended anti-estrogen therapy for ER+, early-stage breast cancer patients.
Recently, Lisa’s found herself with limited free time, between her consuming professional career and training for the IRONMAN held in Lake Placid last weekend.
Fighting cancer can be complicated. Whether you are just beginning your journey to fight estrogen receptor positive (ER+) breast cancer or are approaching your 5 year anniversary and are wondering what’s next, you have options to consider and discuss with your healthcare team.
To help supplement the conversations with your physician, below, we have included some helpful information and links from trusted sources about each stage in your journey to fight early stage ER+ breast cancer.
ASCO is the largest (30,000+ oncology professionals) cancer meeting for sharing new scientific findings that may alter the way patients are diagnosed, treated and followed.
This year’s ASCO, which focused on patient-centered care and research, featured many important developments in the field of ER+ breast cancer.
We reviewed 150+ data presentations and have summarized some of the diagnostic, treatment and side effect management presentations to share with you.